Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Phathom Pharmaceuticals (PHAT) Operating Margin (2022 - 2026)

Phathom Pharmaceuticals (PHAT) has disclosed Operating Margin for 5 consecutive years, with 26.55% as the latest value for Q1 2026.

  • For Q1 2026, Operating Margin rose 24998.0% year-over-year to 26.55%; the TTM value through Mar 2026 reached 47.15%, up 30269.0%, while the annual FY2025 figure was 91.36%, 41082.0% up from the prior year.
  • Operating Margin hit 26.55% in Q1 2026 for Phathom Pharmaceuticals, down from 10.29% in the prior quarter.
  • Across five years, Operating Margin topped out at 1373.9% in Q1 2022 and bottomed at 10245.6% in Q4 2023.
  • Average Operating Margin over 5 years is 926.45%, with a median of 91.27% recorded in 2025.
  • Year-over-year, Operating Margin tumbled -1073135bps in 2023 and then skyrocketed 1004530bps in 2024.
  • Phathom Pharmaceuticals' Operating Margin stood at 485.75% in 2022, then crashed by -2209bps to 10245.6% in 2023, then surged by 98bps to 200.3% in 2024, then skyrocketed by 95bps to 10.29% in 2025, then tumbled by -158bps to 26.55% in 2026.
  • According to Business Quant data, Operating Margin over the past three periods came in at 26.55%, 10.29%, and 30.85% for Q1 2026, Q4 2025, and Q3 2025 respectively.